Northwest Biotherapeutics Statistics
Total Valuation
Northwest Biotherapeutics has a market cap or net worth of 341.69 million. The enterprise value is 412.96 million.
| Market Cap | 341.69M |
| Enterprise Value | 412.96M |
Important Dates
The next estimated earnings date is Thursday, March 6, 2025.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Northwest Biotherapeutics has 1.31 billion shares outstanding. The number of shares has increased by 10.13% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.31B |
| Shares Change (YoY) | +10.13% |
| Shares Change (QoQ) | +3.64% |
| Owned by Insiders (%) | 8.44% |
| Owned by Institutions (%) | 0.05% |
| Float | 1.20B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 196.45 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.82 |
| EV / Sales | 258.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.49 |
Financial Position
The company has a current ratio of 0.09
| Current Ratio | 0.09 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.06 |
| Interest Coverage | -9.68 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -129.81% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 63,840 |
| Profits Per Employee | -2.84M |
| Employee Count | 25 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.10% in the last 52 weeks. The beta is -0.59, so Northwest Biotherapeutics's price volatility has been lower than the market average.
| Beta (5Y) | -0.59 |
| 52-Week Price Change | -65.10% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.38 |
| Relative Strength Index (RSI) | 43.49 |
| Average Volume (20 Days) | 2,719,537 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 21.42 |
Income Statement
In the last 12 months, Northwest Biotherapeutics had revenue of 1.60 million and -71.01 million in losses. Loss per share was -0.06.
| Revenue | 1.60M |
| Gross Profit | -30.22M |
| Operating Income | -63.15M |
| Pretax Income | -69.53M |
| Net Income | -71.01M |
| EBITDA | -61.42M |
| EBIT | -63.15M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 2.94 million in cash and 58.34 million in debt, giving a net cash position of -55.40 million or -0.04 per share.
| Cash & Cash Equivalents | 2.94M |
| Total Debt | 58.34M |
| Net Cash | -55.40M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -64.24M |
| Book Value Per Share | -0.06 |
| Working Capital | -54.37M |
Cash Flow
In the last 12 months, operating cash flow was -53.79 million and capital expenditures -1.35 million, giving a free cash flow of -55.15 million.
| Operating Cash Flow | -53.79M |
| Capital Expenditures | -1.35M |
| Free Cash Flow | -55.15M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,956.83% |
| Pretax Margin | -4,356.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Northwest Biotherapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.13% |
| Shareholder Yield | -10.13% |
| Earnings Yield | -23.25% |
| FCF Yield | -16.14% |
Stock Splits
The last stock split was on September 26, 2012. It was a reverse split with a ratio of 0.0625.
| Last Split Date | Sep 26, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.0625 |
Scores
Northwest Biotherapeutics has an Altman Z-Score of -72.72. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -72.72 |
| Piotroski F-Score | n/a |